Tens of thousands of breast cancer survivors across the United States received a small implanted device called the BioZorb marker after lumpectomy surgery — and many of them are now learning it may have caused serious, lasting harm. The BioZorb lawsuit landscape shifted dramatically on January 7, 2026, when Hologic Inc. executed a formal global settlement agreement covering the more than 200 federal and state court cases consolidated before Judge Allison D. Burroughs in Massachusetts. If you or a loved one received this device, understanding what happened, how the recall unfolded, and where the litigation stands right now is critical to protecting your rights.
What Is the BioZorb Device and How Was It Supposed to Work?
The BioZorb 3D Bioabsorbable Marker was a small, coiled implant designed to be placed directly at the tumor-removal site immediately after a lumpectomy procedure. It consisted of a biodegradable spacer made from polylactic acid wound around six permanent titanium clips. The device’s core promise was straightforward: the polylactic acid framework would gradually dissolve inside the body over time, leaving only the titanium clips in place to serve as permanent landmarks guiding radiation oncologists toward the precise area requiring treatment. For breast cancer patients navigating the already grueling process of post-surgical radiation therapy, that level of precision sounded like a meaningful medical advance.
Hologic Inc. — which acquired the device from its original developer Focal Therapeutics — marketed BioZorb widely to surgical oncologists performing lumpectomies. Radiation therapy targeting after breast-conserving surgery is a standard and well-established part of breast cancer treatment, and the clips left by BioZorb were intended to make that targeting more accurate. What patients were not adequately warned about, lawsuits allege, is what would happen when the bioabsorption process failed. To estimate the value of injuries caused by defective medical devices, many patients are now using a medical malpractice calculator as a starting point when evaluating their potential claims.
How the BioZorb Device Failed: Alleged Defects and Injuries
Rather than dissolving cleanly as designed, the BioZorb device allegedly failed to resorb properly in a significant number of patients. Lawsuits filed across the country describe a consistent and alarming pattern of device failure. Instead of breaking down, the implant migrated inside the body, eroded through the skin, triggered persistent infections, caused chronic pain, produced seromas (fluid-filled pockets), and led to scarring and disfigurement requiring additional surgical intervention. For women who had already endured cancer diagnosis, surgery, and radiation, these complications represented a devastating second trauma.
The alleged harm did not stop at migration and erosion. Court complaints also raised concerns that the BioZorb device, when present during radiation treatment, may have amplified the skin radiation dose delivered during therapy. This amplification effect, plaintiffs alleged, could cause radiation skin reactions, permanent scarring, and a vascular skin condition called telangiectasia — spider-like blood vessel damage visible on the surface of the skin. These are injuries that could persist for the rest of a patient’s life. Since 2015, nearly 400 complaints were filed with the FDA by patients and healthcare providers raising concerns about these exact outcomes.
BioZorb Recall Timeline: From Voluntary Action to Class I FDA Recall
The regulatory history of the BioZorb recall follows a progression that grew increasingly serious over the course of 2024. The table below summarizes the key events in the recall and litigation timeline:
| Date | Event | Significance |
|---|---|---|
| Since 2015 | ~399 complaints filed with FDA; 188 involving adverse events | Ongoing regulatory signal accumulating for years |
| May 2024 | Hologic issues voluntary recall | First formal step acknowledging device concerns |
| October 2024 | Hologic asks physicians to quarantine and stop using BioZorb entirely | Complete cessation of device use in clinical practice |
| December 18, 2024 | FDA issues formal Class I recall of BioZorb 3D Bioabsorbable Markers | Highest-severity FDA recall classification; potential for serious injury or death |
| November 2025 | Parties reach agreement in principle, disclosed to court | Global settlement framework announced before bellwether trials |
| January 7, 2026 | Formal settlement agreement executed | Binding resolution conditioned on plaintiff participation threshold |
The FDA’s Class I recall classification — the agency’s most serious category — reflects a determination that use of or exposure to a product carries a reasonable probability of causing serious adverse health consequences or death. That designation, issued on December 18, 2024, placed the BioZorb device in the same regulatory category as the most dangerous recalled products on the market.
The BioZorb Lawsuit Litigation: Consolidation, Key Rulings, and the Path to Settlement
Approximately 200 plaintiffs filed complaints against Hologic, with one case in Massachusetts state court and the remainder in the U.S. District Court for the District of Massachusetts. Though the cases were not consolidated as a formal multidistrict litigation (MDL), they were assigned to Judge Allison D. Burroughs, who presided over the coordinated proceedings. Plaintiffs alleged design defects, inadequate warnings, and manufacturing failures. A critical turning point came when Judge Burroughs denied Hologic’s motions for summary judgment, finding that plaintiffs had presented a triable question on causation — a ruling that meaningfully strengthened the plaintiffs’ negotiating position.
With the first bellwether trial originally set for September 8, 2025, and a second scheduled for January 2026, the litigation was approaching its most consequential phase when the parties reached an agreement in principle in November 2025. Hologic disclosed the formal execution of a settlement agreement on January 7, 2026, through an SEC Form 8-K filing — without any admission of liability. The BioZorb lawsuit settlement is fully covered by Hologic’s insurance, meaning the company expects to bear no direct financial liability. The agreement is conditioned on a participation threshold: if a sufficient percentage of eligible plaintiffs join the settlement, the cases will be dismissed with prejudice.
For families considering how broader personal injury settlement structures compare across different types of cases, reviewing a personal injury settlement calculator can help contextualize how settlement values are typically determined across factors like severity of injury, duration of suffering, and required medical care.
Who Still Qualifies for the BioZorb Settlement in 2026?
The core class of plaintiffs in the BioZorb lawsuit settlement consists of women who received the BioZorb device after lumpectomy and subsequently experienced documented injuries including device migration, infection, skin erosion, seroma formation, chronic pain, or who required revision or removal surgery. Lawsuits alleging radiation dose amplification and resulting skin damage — including telangiectasia and scarring — are also within the alleged injury profile covered by these proceedings.
As of early 2026, some attorneys handling BioZorb claims have reported that new case intake is no longer being actively reviewed at certain firms, suggesting that the window for joining the litigation may be narrowing. However, the settlement’s participation threshold condition means that the resolution process is still actively underway and has not yet closed. Women who received BioZorb implants and experienced complications should take immediate steps to document their medical records, gather surgical reports, and consult qualified legal counsel. The statute of limitations applicable to medical device injury claims varies by state; Cornell Law School’s Legal Information Institute provides a useful overview of how statutes of limitations apply in civil injury contexts.
What Compensation Can BioZorb Plaintiffs Realistically Expect?
Because the BioZorb lawsuit settlement terms have not been publicly disclosed in detail — consistent with standard practice in mass tort global resolutions — specific individual compensation figures are not publicly available. What is known is that the settlement is fully funded by Hologic’s insurance coverage, which suggests the aggregate fund is substantial enough to cover the more than 200 consolidated cases. In mass tort device settlements, individual recoveries are typically tiered based on injury severity, documented medical expenses, duration and nature of suffering, and the extent of any permanent physical consequences.
Women who underwent device removal surgery, required treatment for infections or erosions, suffered radiation complications, or experienced long-term disfigurement generally receive higher compensation within settlement grids than those with less severe documented injuries. Medical records, surgical notes, imaging studies, and treating physician statements are the evidentiary building blocks of individual valuations in proceedings like this. The BioZorb lawsuit settlement structure — fully insured and designed to resolve the substantial majority of cases with finality — reflects the litigation pressure that had built from Judge Burroughs’ denial of summary judgment through the looming bellwether trial calendar.
Frequently Asked Questions About the BioZorb Lawsuit
What exactly caused the BioZorb device to fail?
Lawsuits allege that the polylactic acid framework of the BioZorb device failed to dissolve and bioabsorb as designed and marketed. Instead of breaking down harmlessly, the device allegedly migrated within the body, eroded through skin tissue, and caused infections, chronic pain, seromas, and scarring. Some complaints also allege that the device amplified skin radiation dose during post-lumpectomy radiation therapy, causing additional skin injuries including telangiectasias and permanent scarring. The FDA’s Class I recall — its most serious classification — was issued on December 18, 2024, based on the device’s potential to cause serious injury or death.
Is the BioZorb settlement still accepting new claimants in 2026?
The formal settlement agreement was executed on January 7, 2026, and is conditioned on a participation threshold being met — meaning the resolution process is ongoing but not fully closed. However, some attorneys have reported that new claim intake is no longer being actively accepted at certain firms. Women who experienced BioZorb complications should act quickly to consult qualified legal counsel and preserve all relevant medical records, as windows for participation may be time-limited and statutes of limitations apply.
Does Hologic admit wrongdoing in the BioZorb settlement?
No. Hologic’s SEC Form 8-K filing disclosing the January 7, 2026 settlement agreement explicitly states that the settlement was entered without any admission of liability by Hologic. This is standard practice in mass tort medical device resolutions, where manufacturers frequently settle litigation to achieve finality and avoid trial risk without conceding fault. The absence of a liability admission does not affect the legal validity of the settlement or the compensation paid to qualifying plaintiffs.
Who is eligible to participate in the BioZorb lawsuit settlement?
Eligible plaintiffs are generally women who received the BioZorb 3D Bioabsorbable Marker device after lumpectomy surgery and suffered documented injuries as a result. Core injuries in the litigation include device migration, infection, skin erosion, seroma, chronic pain, scarring, disfigurement, and complications related to radiation therapy amplification. Women who required surgical revision or device removal are also among the primary claimants. Individual eligibility depends on the specific facts, medical documentation, and timing of the claim relative to applicable statutes of limitations.
How much money could a BioZorb lawsuit settlement pay individual plaintiffs?
Specific individual settlement amounts have not been publicly disclosed. The settlement fund is fully covered by Hologic’s insurance, and the company has stated it expects no direct financial liability. In mass tort device settlements of this type, compensation is typically tiered by injury severity — with higher amounts awarded for surgical removal, documented infections, radiation-related skin damage, permanent disfigurement, and ongoing medical treatment. Plaintiffs with comprehensive medical documentation generally fare better within settlement allocation grids. Consulting an attorney with mass tort experience is the most reliable way to understand what an individual claim may be worth.
This content is provided for general informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction regarding the specific facts of your situation.
Related reading: Independent Medical Examination (IME) In Medical Malpractice: How The Defense Doctor Can Make Or Break Your Claim (2026)
Related reading: Ambulatory Surgery Center Malpractice Settlement Amounts: 2026 Data, Verdicts & How ASC Liability Is Calculated
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.